Impact of EpsteinBarr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients

Nephrology Dialysis Transplantation

Volumn 27, Issue 7, 2012, Pages 2971-2979

  Sampaio, Marcelo Santos ^a   Cho, Yong W ^a   Shah, Tariq ^a,b   Bunnapradist, Suphamai ^c   Hutchinson, Ian V ^a,d  

^a National Institute of Transplantation Los Angeles   (United States)

^b ST VINCENT MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

EpsteinBarr virus; OPTN UNOS; post transplant lymphoproliferative disorder; renal transplantation; transplant outcomes

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; DACLIZUMAB; OKT 3; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CAUSE OF DEATH; DONOR SELECTION; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; SURVIVAL RATE; TREATMENT OUTCOME; ADOLESCENT; BLOOD; CHILD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DONOR; EPSTEIN BARR VIRUS; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; MIDDLE AGED; MORTALITY; PROGNOSIS; RECURRENT DISEASE; UNITED STATES; VIROLOGY;

ADOLESCENT; ADULT; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HERPESVIRUS 4, HUMAN; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; LOS ANGELES; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RECURRENCE; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE; TISSUE DONORS; YOUNG ADULT;

EID: 84861976418     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr769     Document Type: Article

References (23)

1. Libertiny G, Watson CJ, Gray DW et al. Rising incidence of posttransplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001; 88: 1330-1334.
2. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222-230.
3. Parker A, Bowles K, Bradley JA et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 2010; 149: 675-692.
4. Trofe J, Buell JF, Beebe TM et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5(4 Pt 1): 775-780.
5. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010; 23: 350-366.
6. Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant 2008; 8: 2205-2211.
7. Snow AL, Martinez OM. Epstein-Barr virus: evasive maneuvers in the development of PTLD. Am J Transplant 2007; 7: 271-277.
8. Allen U, Preiksaitis J. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S87-S96.
9. Weikert BC, Blumberg EA. Viral infection after renal transplantation: surveillance and management. Clin J Am Soc Nephrol 2008; 3(Suppl 2): S76-S86.
10. Center for Disease Control and Prevention-National Center for Infectious Diseases. Epstein-Barr Virus and Infectious Mononucleosis http://www.cdc.gov/ ncidod/diseases/ebv.htm (2 November 2011, date last accessed).
11. Macsween KF, Crawford DH. Epstein-Barr virus-recent advances. Lancet Infect Dis 2003; 3: 131-140.
12. Allen UD. Epstein-barr virus vaccination of transplant candidates: light at the end of the tunnel? Transplantation 2009; 88: 976-977.
13. Wang FZ, Roy D, Gershburg E et al. Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication. J Virol 2009; 83: 12108-12117.
14. Gershburg E, Pagano JS. Epstein-Barr virus infections: prospects for treatment. J Antimicrob Chemother 2005; 56: 277-281.
15. Rees L, Tizard EJ, Morgan AJ et al. A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 2009; 88: 1025-1029.
16. Jung S, Chung YK, Chang SH et al. DNA-mediated immunization of glycoprotein 350 of Epstein-Barr virus induces the effective humoral and cellular immune responses against the antigen. Mol Cells 2001; 12: 41-49.
17. Vallhov H, Gutzeit C, Johansson SM et al. Exosomes containing glycoprotein 350 released by EBV-transformed B cells selectively target B cells through CD21 and block EBV infection in vitro. J Immunol 2011; 186: 73-82.
18. Green M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103-108.
19. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-274.
20. McDonald RA, Smith JM, Ho M et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8: 984-989.
21. Dharnidharka VR, Tejani AH, Ho PL et al. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant 2002; 2: 993-998.
22. Koleilat I, Kushnir L, Gallichio M et al. Initiation of a screening protocol for polyoma virus results in a decreased rate of opportunistic non-BK viral disease after renal transplantation. Transpl Infect Dis 2011; 13: 1-8.
23. Funch DP, Walker AM, Schneider G et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894-2900.